Pluripotent stem cells: The last 10 years

Regenerative Medicine

Volumn 11, Issue 8, 2016, Pages 831-847

  Kimbrel, Erin A ^a   Lanza, Robert ^a  

^a Astellas Institute of Regenerative Medicine   (United States)

Author keywords

clinical trials; disease in a dish models; drug screening; embryonic stem cells; gene editing; induced pluripotent stem cells

Indexed keywords

BIOTECHNOLOGY; CELL DIFFERENTIATION; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG DEVELOPMENT; EMBRYONIC STEM CELL; GENETIC MANIPULATION; HUMAN; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; ANIMAL; CYTOLOGY; PROCEDURES; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING;

ANIMALS; HUMANS; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING;

EID: 85001968821     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme-2016-0117     Document Type: Review

References (129)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 282(5391), 1145-1147 (1998).
2. Little M, Hall W, Orlandi A. Delivering on the promise of human stem-cell research. What are the real barriers? EMBO Rep. 7(12), 1188-1192 (2006).
3. Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 366(9502), 2019-2025 (2005).
4. Chung Y, Klimanskaya I, Becker S et al. Embryonic and extraembryonic stem cell lines derived from single mouse blastomeres. Nature 439(7073), 216-219 (2006).
5. Klimanskaya I, Chung Y, Becker S, Lu S-J, Lanza R. Human embryonic stem-cell lines derived from single blastomeres. Nature 444, 481-485 (2006).
6. Handyside AH, Kontogianni EH, Hardy K, Winston RM. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. Nature 344(6268), 768-770 (1990).
7. Mcarthur SJ, Leigh D, Marshall JT, Gee AJ, De Boer KA, Jansen RP. Blastocyst trophectoderm biopsy and preimplantation genetic diagnosis for familial monogenic disorders and chromosomal translocations. Prenat. Diagn. 28(5), 434-442 (2008).
8. Ilic D, Giritharan G, Zdravkovic T et al. Derivation of human embryonic stem cell lines from biopsied blastomeres on human feeders with minimal exposure to xenomaterials. Stem Cells Dev. 18(9), 1343-1350 (2009).
9. Cibelli JB, Stice SL, Golueke PJ et al. Cloned transgenic calves produced from nonquiescent fetal fibroblasts. Science 280(5367), 1256-1258 (1998).
10. Onishi A, Iwamoto M, Akita T et al. Pig cloning by microinjection of fetal fibroblast nuclei. Science 289(5482), 1188-1190 (2000).
11. Wakayama S, Kohda T, Obokata H et al. Successful serial recloning in the mouse over multiple generations. Cell Stem Cell 12(3), 293-297 (2013).
12. Tachibana M, Amato P, Sparman M et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 153(6), 1228-1238 (2013).
13. Chung YG, Eum JH, Lee JE et al. Human somatic cell nuclear transfer using adult cells. Cell Stem Cell 14(6), 777-780 (2014).
14. Yamada M, Johannesson B, Sagi I et al. Human oocytes reprogram adult somatic nuclei of a type 1 diabetic to diploid pluripotent stem cells. Nature 510(7506), 533-536 (2014).
15. Times TK. Resumed stem cell study (2016). www.koreatimes.co.kr/
16. Chung YG, Matoba S, Liu Y et al. Histone demethylase expression enhances human somatic cell nuclear transfer efficiency and promotes derivation of pluripotent stem cells. Cell Stem Cell 17(6), 758-766 (2015).
17. Gurdon JB, Wilmut I. Nuclear transfer to eggs and oocytes. Cold Spring Harb. Perspect. Biol. 3(6), pii: a002659 (2011).
18. Jullien J, Pasque V, Halley-Stott RP, Miyamoto K, Gurdon JB. Mechanisms of nuclear reprogramming by eggs and oocytes: a deterministic process? Nat. Rev. Mol. Cell Biol. 12(7), 453-459 (2011).
19. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006).
20. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5), 861-872 (2007).
21. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858), 1917-1920 (2007).
22. The Nobel Prize in Physiology or Medicine 2012: Sir John B. Gurdon and Shinya Yamanaka. www.nobelprize.org/
23. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858), 1917-1920 (2007).
24. Aoki T, Ohnishi H, Oda Y et al. Generation of induced pluripotent stem cells from human adipose-derived stem cells without c-MYC. Tissue Eng. 16(7), 2197-2206 (2010).
25. Nakagawa M, Koyanagi M, Tanabe K et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 26(1), 101-106 (2008).
26. Zhao HX, Li Y, Jin HF et al. Rapid and efficient reprogramming of human amnion-derived cells into pluripotency by three factors OCT4/SOX2/NANOG. Differentiation 80(2-3), 123-129 (2010).
27. Giorgetti A, Montserrat N, Aasen T et al. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell 5(4), 353-357 (2009).
28. Kim JB, Greber B, Arauzo-Bravo MJ et al. Direct reprogramming of human neural stem cells by OCT4. Nature 461(7264), 649-643 (2009).
29. Warren L, Manos PD, Ahfeldt T et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7(5), 618-630 (2010).
30. Kim D, Kim CH, Moon JI et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4(6), 472-476 (2009).
31. Yu J, Hu K, Smuga-Otto K et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 324(5928), 797-801 (2009).
32. Okita K, Matsumura Y, Sato Y et al. A more efficient method to generate integration-free human iPS cells. Nat. Methods 8(5), 409-412 (2011).
33. Jia F, Wilson KD, Sun N et al. A nonviral minicircle vector for deriving human iPS cells. Nat. Methods 7(3), 197-199 (2010).
34. Woltjen K, Michael IP, Mohseni P et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458(7239), 766-770 (2009).
35. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 85(8), 348-362 (2009).
36. Shi Y, Do JT, Desponts C, Hahm HS, Scholer HR, Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2(6), 525-528 (2008).
37. Huangfu D, Maehr R, Guo W et al. Induction of pluripotent stem cells by defined factors is greatly improved by smallmolecule compounds. Nat. Biotechnol. 26(7), 795-797 (2008).
38. Hou P, Li Y, Zhang X et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 341(6146), 651-654 (2013).
39. Yamanaka S. A fresh look at iPS cells. Cell 137(1), 13-17 (2009).
40. Hu BY, Weick JP, Yu J et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl Acad. Sci. USA 107(9), 4335-4340 (2010).
41. Feng Q, Lu SJ, Klimanskaya I et al. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells 28(4), 704-712 (2010).
42. Kim K, Zhao R, Doi A et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat. Biotechnol. 29(12), 1117-1119 (2011).
43. Bar-Nur O, Russ HA, Efrat S, Benvenisty N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell 9(1), 17-23 (2011).
44. Lister R, Pelizzola M, Kida YS et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471(7336), 68-73 (2011).
45. Polo JM, Liu S, Figueroa ME et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 28(8), 848-855 (2010).
46. Kim K, Doi A, Wen B et al. Epigenetic memory in induced pluripotent stem cells. Nature 467(7313), 285-290 (2010).
47. Ghosh Z, Wilson KD, Wu Y, Hu S, Quertermous T, Wu JC. Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. PLoS ONE 5(2), e8975 (2010).
48. Chin MH, Mason MJ, Xie W et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5(1), 111-123 (2009).
49. Marchetto MC, Yeo GW, Kainohana O, Marsala M, Gage FH, Muotri AR. Transcriptional signature and memory retention of human-induced pluripotent stem cells. PLoS ONE 4(9), e7076 (2009).
50. Chin MH, Pellegrini M, Plath K, Lowry WE. Molecular analyses of human induced pluripotent stem cells and embryonic stem cells. Cell Stem Cell 7(2), 263-269 (2010).
51. Guenther MG, Frampton GM, Soldner F et al. Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell 7(2), 249-257 (2010).
52. Wang A, Huang K, Shen Y et al. Functional modules distinguish human induced pluripotent stem cells from embryonic stem cells. Stem Cells Dev. 20(11), 1937-1950 (2011).
53. Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10(6), 678-684 (2012).
54. Stadtfeld M, Apostolou E, Ferrari F et al. Ascorbic acid prevents loss of Dlk1-Dio3 imprinting and facilitates generation of all-iPS cell mice from terminally differentiated B cells. Nat. Genet. 44(4), 398-405 (2012).
55. Varughese A. Abandoning the stem cell clinical trial ship. Biotechniques (2011).www.biotechniques.com/
56. Treatment for spinal cord Injury to start clinical trial funded by California's stem cell agency. www.cirm.ca.gov/
57. Asterias Biotherapeutics Completes Enrollment and Dosing for the First Efficacy Cohort of the AST-OPC1 SCiSTAR Phase 1/2a Clinical Trial in Complete Cervical Spinal Cord Injury. http://asteriasbiotherapeutics.com/
58. Biotherapeutics A. Asterias Biotherapeutics Announces Positive New Long-Term Follow-Up Results for AST-OPC1. (2016). http://asteriasbiotherapeutics.com/
59. Schwartz SD, Hubschman JP, Heilwell G et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379(9817), 713-720 (2012).
60. Schwartz SD, Regillo CD, Lam BL et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label Phase 1/2 studies. Lancet 385(9967), 509-516 (2015).
61. Song WK, Park KM, Kim HJ et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in asian patients. Stem Cell Rep. 4(5), 860-872 (2015).
62. Morizane A, Doi D, Kikuchi T et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Rep. 1(4), 283-292 (2013).
63. Sugita S, Iwasaki Y, Makabe K et al. Successful transplantation of retinal pigment epithelial cells from MHC Homozygote iPSCs in MHC-matched models. Stem Cell Rep. 7(4), 635-648 (2016).
64. Garber K. RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nat. Biotechnol. 33(9), 890-891 (2015).
65. The London Project to Cure Blindness. www.thelondonproject.org/
66. California's Stem Cell Agency. www.cirm.ca.gov
67. ClinicalTrials.gov. http://clinicaltrials.gov
68. Kroon E, Martinson LA, Kadoya K et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat. Biotechnol. 26(4), 443-452 (2008).
69. Blin G, Nury D, Stefanovic S et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J. Clin. Invest. 120(4), 1125-1139 (2010).
70. Bellamy V, Vanneaux V, Bel A et al. Long term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold. J. Heart Lung Transplant. 34(9), 1198-1207 (2015).
71. Grealish SE, Diguet A, Kirkeby B et al. Human ESCderived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of parkinson's disease. Cell Stem Cell 15, 653-665 (2014).
72. Kriks S, Shim JW, Piao J et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480(7378), 547-551 (2011).
73. Doi D, Samata B, Katsukawa M et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Rep. 2(3), 337-350 (2014).
74. Hallett PJ, Deleidi M, Astradsson A et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell 16(3), 269-274 (2015).
75. Barker RA, Studer L, Cattaneo E, Takahashi J. G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson's disease. NPJ Parkinson's Dis. 1, 15017 (2015).
76. Abdelalim EM, Emara MM. Advances and challenges in the differentiation of pluripotent stem cells into pancreatic beta cells. World J. Stem Cells 7(1), 174-181 (2015).
77. Pagliuca FW, Millman JR, Gurtler M et al. Generation of functional human pancreatic beta cells in vitro. Cell 159(2), 428-439 (2014).
78. Vegas AJ, Veiseh O, Gurtler M et al. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat. Med. 22(3), 306-311 (2016).
79. Umegaki-Arao N, Pasmooij AM, Itoh M et al. Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa. Sci. Transl. Med. 6(264), 264ra164 (2014).
80. Sebastiano V, Zhen HH, Haddad B et al. Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. Sci. Transl. Med. 6(264), 264ra163 (2014).
81. Barnea-Cramer AO, Wang W, Lu S-J et al. Function of human pluripotent stem cell-derived photoreceptor progenitors in blind mice. Sci. Rep. 6, 29784 (2016).
82. Lamba DA, Karl MO, Ware CB, Reh TA. Efficient generation of retinal progenitor cells from human embryonic stem cells. Proc. Natl Acad. Sci. USA 103(34), 12769-12774 (2006).
83. Osakada F, Ikeda H, Mandai M et al. Toward the generation of rod and cone photoreceptors from mouse, monkey and human embryonic stem cells. Nat.Biotechnol. 26(2), 215-224 (2008).
84. Osakada F, Jin ZB, Hirami Y et al. In vitro differentiation of retinal cells from human pluripotent stem cells by smallmolecule induction. J. Cell Sci. 122(Pt 17), 3169-3179 (2009).
85. Takamatsu K, Ikeda T, Haruta M et al. Degradation of amyloid beta by human induced pluripotent stem cellderived macrophages expressing Neprilysin-2. Stem Cell Res. 13(3PA), 442-453 (2014).
86. Nizzardo M, Bucchia M, Ramirez A et al. iPSC-derived LewisX+CXCR4+beta1-integrin+ neural stem cells improve the amyotrophic lateral sclerosis phenotype by preserving motor neurons and muscle innervation in human and rodent models. Hum. Mol. Genet. doi:10.1093/hmg/ddw163 (2016) (Epub ahead of print).
87. Takebe T, Sekine K, Enomura M et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499(7459), 481-484 (2013).
88. Halevy T, Urbach A. Comparing ESC and iPSC-based models for human genetic disorders. J. Clin. Med. 3(4), 1146-1162 (2014).
89. Research CIFM. CIRM human pluripotent stem cell repository (2016). www.cirm.ca.gov/
90. Foundation NYSC. Stem cell search (2016). http://nyscf.org/
91. Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. Nat. Rev. Mol. Cell Biol. 17(3), 170-182 (2016).
92. Consortium HDi. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeatexpansion-associated phenotypes. Cell Stem Cell 11(2), 264-278 (2012).
93. Young JE, Boulanger-Weill J, Williams DA et al. Elucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell 16(4), 373-385 (2015).
94. Zhong X, Gutierrez C, Xue T et al. Generation of threedimensional retinal tissue with functional photoreceptors from human iPSCs. Nat. Commun. 5, 4047 (2014).
95. Jo J, Xiao Y, Sun AX et al. Midbrain-like organoids from human pluripotent stem cells contain functional dopaminergic and neuromelanin-producing neurons. Cell Stem Cell 19(2), 248-257 (2016).
96. Somers A, Jean JC, Sommer CA et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 28(10), 1728-1740 (2010).
97. Wilkinson DC, Alva-Ornelas JA, Sucre JM et al. Development of a three-dimensional bioengineering technology to generate lung tissue for personalized disease modeling. Stem Cells Transl. Med. doi:10.5966/sctm.2016-0192 (2016) (Epub ahead of print).
98. Spence JR, Mayhew CN, Rankin SA et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 470(7332), 105-109 (2011).
99. Takasato M, Er PX, Chiu HS et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature 526(7574), 564-568 (2015).
100. Kurmann AA, Serra M, Hawkins F et al. Regeneration of thyroid function by transplantation of differentiated pluripotent stem cells. Cell Stem Cell 17(5), 527-542 (2015).
101. Scott CW, Peters MF, Dragan YP. Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. Toxicol. Lett. 219(1), 49-58 (2013).
102. Egawa N, Kitaoka S, Tsukita K et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 4(145), 145ra104 (2012).
103. Lee G, Ramirez CN, Kim H et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat. Biotechnol. 30(12), 1244-1248 (2012).
104. Mathur A, Loskill P, Shao K et al. Human iPSC-based cardiac microphysiological system for drug screening applications. Sci. Rep. 5, 8883 (2015).
105. Liang P, Lan F, Lee AS et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127(16), 1677-1691 (2013).
106. Sirenko O, Hesley J, Rusyn I, Cromwell EF. High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells. Assay Drug Dev. Technol. 12(1), 43-54 (2014).
107. Hendriks WT, Warren CR, Cowan CA. Genome editing in human pluripotent stem cells: approaches, pitfalls, and solutions. Cell Stem Cell 18(1), 53-65 (2016).
108. Paquet D, Kwart D, Chen A et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature 533(7601), 125-129 (2016).
109. Song B, Fan Y, He W et al. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system. Stem Cells Dev. 24(9), 1053-1065 (2015).
110. Wang D, Quan Y, Yan Q, Morales JE, Wetsel RA. Targeted disruption of the beta2-microglobulin gene minimizes the immunogenicity of human embryonic stem cells. Stem Cells Transl. Med. 4(10), 1234-1245 (2015).
111. Riolobos L, Hirata RK, Turtle CJ et al. HLA engineering of human pluripotent stem cells. Mol. Ther. 21(6), 1232-1241 (2013).
112. Feng Q, Shabrani N, Thon JN et al. Scalable generation of universal platelets from human induced pluripotent stem cells. Stem Cell Rep. 3(5), 817-831 (2014).
113. Meissner T, Strominger J, Cowan C. The universal donor stem cell: removing the immune barrier to transplantation using CRISPR/Cas9 (TRAN1P.946). J. Immunol. 194(Suppl. 1), 140.28 (2015).
114. Kondo T, Asai M, Tsukita K et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell 12(4), 487-496 (2013).
115. Drowley L, Koonce C, Peel S et al. Human induced pluripotent stem cell-derived cardiac progenitor cells in phenotypic screening: a transforming growth factor-beta type 1 receptor kinase inhibitor induces efficient cardiac differentiation. Stem Cells Transl. Med. 5(2), 164-174 (2016).
116. Fong AH, Romero-Lopez M, Heylman CM et al. Threedimensional adult cardiac extracellular matrix promotes maturation of human induced pluripotent stem cell-derived cardiomyocytes. Tissue Eng. 22(15-16), 1016-1025 (2016).
117. Gieseck RL 3rd, Hannan NR, Bort R et al. Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture. PLoS ONE 9(1), e86372 (2014).
118. Zou J, Maeder ML, Mali P et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5(1), 97-110 (2009).
119. Hockemeyer D, Soldner F, Beard C et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 27(9), 851-857 (2009).
120. Smith C, Abalde-Atristain L, He C et al. Efficient and allelespecific genome editing of disease loci in human iPSCs. Mol. Ther. 23(3), 570-577 (2015).
121. Gonzalez F, Zhu Z, Shi ZD et al. An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell 15(2), 215-226 (2014).
122. Khan IF, Hirata RK, Wang PR et al. Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol. Ther. 18(6), 1192-1199 (2010).
123. ClincalTrials.gov. www.clinicaltrials.gov
124. Edelstein M. Gene therapy clinical trials worldwide. (2016). www.abedia.com/wiley/vectors.php
125. Wang Y, Liang P, Lan F et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J. Am. Coll. Cardiol. 64(5), 451-459 (2014).
126. Horizon. www.horizondiscovery.com
127. Bassuk AG, Zheng A, Li Y, Tsang SH, Mahajan VB. Precision medicine: genetic repair of retinitis pigmentosa in patient-derived stem cells. Sci. Rep. 6, 19969 (2016).
128. Universal Cells. www.universalcells.com
129. Weissbein U, Benvenisty N, Ben-David U. Quality control: genome maintenance in pluripotent stem cells. J. Cell Biol. 204(2), 153-163 (2014).